The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research

被引:4
作者
Ketchum, Fred B. [1 ]
Chin, Nathaniel A. [2 ,3 ]
Erickson, Claire [4 ]
Lambrou, Nickolas H. [2 ]
Basche, Kristin [2 ]
Gleason, Carey E. [2 ,3 ,5 ]
Clark, Lindsay [2 ,3 ,5 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, 1675 Highland, Madison, WI 53705 USA
[2] Univ Wisconsin, Dept Med, Div Geriatr, Sch Med & Publ Hlth, Madison, WI 53705 USA
[3] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA
[4] Univ Penn, Dept Med Ethics & Hlth Policy, Perelman Sch Med, Philadelphia, PA USA
[5] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA
关键词
Alzheimer's disease; biomarkers; disclosure; ethics; preclinical diagnosis; DEMENTIA; STIGMA;
D O I
10.1002/trc2.12416
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUNDIn the asymptomatic "preclinical" phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed to participants in research settings, and biomarker testing and results disclosure will be implemented in clinical settings in the future. Biomarker disclosure has potential psychosocial benefits and harms, impacting affected individuals and their support person(s). Limited data are available about with whom research participants share their results, information that will be necessary to develop disclosure protocols and post-disclosure resources. Additionally, existing research has been conducted in largely White cohorts, limiting applicability to future clinical populations. METHODSWe enrolled a diverse cohort of 329 adults (184 non-Hispanic White and 145 Black/African American individuals) who previously participated in AD research. After reviewing a vignette describing a hypothetical biomarker research study, participants indicated their anticipated willingness to share biomarker results with loved ones, and what reactions they anticipated from others. Using mixed-methods analysis, we identified responses related to willingness to share results. RESULTSA majority (78.7%) were willing to share their results with support persons. Many (59.6%) felt it would not be difficult to share, and most (90.6%) believed their loved ones would be supportive. The most common reasons for sharing were to prepare for possible future AD (41.0% of respondents), while the most common reason for not sharing was to avoid worrying loved ones (4.8% of respondents). A total of 7.3% of respondents related reasons regarding being unsure about sharing. DISCUSSIONParticipants' interest in sharing results supports integrating support persons into AD biomarker research, and may help maximize potential benefits for participants. Communicating with this "dyad" of research participant and support person(s) may improve involvement in research, and help prepare for implementation of clinical biomarker testing by clarifying communication preferences and the influence of support persons on psychosocial outcomes.
引用
收藏
页数:11
相关论文
共 53 条
  • [21] Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment
    Grill, Joshua D.
    Raritan, Rema
    Ernstrom, Karin
    Sultzer, David L.
    Bums, Jeffrey M.
    Donohue, Michael C.
    Johnson, Keith A.
    Aisen, Paul S.
    Sperling, Reisa A.
    Karlawish, Jason
    [J]. JAMA NEUROLOGY, 2020, 77 (12) : 1504 - 1513
  • [22] Study partners should be required in preclinical Alzheimer's disease trials
    Grill, Joshua D.
    Karlawish, Jason
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [23] Into the Prodrome: Diagnosis, Disadvantage, and Biomedical Ambiguity
    Halpin, Michael Allan
    [J]. SOCIETY AND MENTAL HEALTH, 2021, 11 (01) : 38 - 53
  • [24] Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
    Hampel, Harald
    O'Bryant, Sid E.
    Molinuevo, Jose L.
    Zetterberg, Henrik
    Masters, Colin L.
    Lista, Simone
    Kiddle, Steven J.
    Batrla, Richard
    Blennow, Kaj
    [J]. NATURE REVIEWS NEUROLOGY, 2018, 14 (11) : 639 - 652
  • [25] A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
    Jack, Clifford R., Jr.
    Bennett, David A.
    Blennow, Kaj
    Carrillo, Maria C.
    Feldman, Howard H.
    Frisoni, Giovanni B.
    Hampel, Harald
    Jagust, William J.
    Johnson, Keith A.
    Knopman, David S.
    Petersen, Ronald C.
    Scheltens, Philip
    Sperling, Reisa A.
    Dubois, Bruno
    [J]. NEUROLOGY, 2016, 87 (05) : 539 - 547
  • [26] NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
    Jack, Clifford R., Jr.
    Bennett, David A.
    Blennow, Kaj
    Carrillo, Maria C.
    Dunn, Billy
    Haeberlein, Samantha Budd
    Holtzman, David M.
    Jagust, William
    Jessen, Frank
    Karlawish, Jason
    Liu, Enchi
    Luis Molinuevo, Jose
    Montine, Thomas
    Phelps, Creighton
    Rankin, Katherine P.
    Rowe, Christopher C.
    Scheltens, Philip
    Siemers, Eric
    Snyder, Heather M.
    Sperling, Reisa
    Elliott, Cerise
    Masliah, Eliezer
    Ryan, Laurie
    Silverberg, Nina
    [J]. ALZHEIMERS & DEMENTIA, 2018, 14 (04) : 535 - 562
  • [27] Johnson Sterling C, 2018, Alzheimers Dement (Amst), V10, P130, DOI 10.1016/j.dadm.2017.11.007
  • [28] Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts
    Karikari, Thomas K.
    Pascoal, Tharick A.
    Ashton, Nicholas J.
    Janelidze, Shorena
    Benedet, Andrea Lessa
    Rodriguez, Juan Lantero
    Chamoun, Mira
    Savard, Melissa
    Kang, Min Su
    Therriault, Joseph
    Scholl, Michael
    Massarweh, Gassan
    Soucy, Jean-Paul
    Hoglund, Kina
    Brinkmalm, Gunnar
    Mattsson, Niklas
    Palmqvist, Sebastian
    Gauthier, Serge
    Stomrud, Erik
    Zetterberg, Henrik
    Hansson, Oskar
    Rosa-Neto, Pedro
    Blennow, Kaj
    [J]. LANCET NEUROLOGY, 2020, 19 (05) : 422 - 433
  • [29] What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis
    Ketchum, Fred B.
    Erickson, Claire M.
    Chin, Nathaniel A.
    Gleason, Carey E.
    Lambrou, Nickolas H.
    Benton, Susan Flowers
    Clark, Lindsay R.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2022, 87 (03) : 1167 - 1179
  • [30] Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
    Ketchum, Fred B.
    Chin, Nathaniel A.
    Grill, Joshua
    Gleason, Carey E.
    Erickson, Claire
    Clark, Lindsay R.
    Paulsen, Jane S.
    Kind, Amy J. H.
    [J]. ALZHEIMERS & DEMENTIA, 2022, 18 (10) : 1969 - 1979